일리노이의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 21개가 일리노이 내 여러 지역에서 참여자를 모집하고 있습니다.
일리노이의 도시
공식 연구 텍스트(영어)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University of Illinois Cancer Center ( Site 0044), Chicago
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Southern Illinois Hospital Services ( Site 9554), Carterville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Illinois Cancer Specialists (ICS) ( Site 8010), Arlington Heights
- Southern Illinois Hospital Services ( Site 9547), Carterville
- Orchard Healthcare Research Inc. ( Site 0014), Skokie
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06393374A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06465069Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05633654Study of XB010 in Subjects With Solid Tumors
- University of Chicago Medical Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06545331A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- UChicago Medicine Comprehensive Cancer Center, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06908928SMP-3124LP in Adults With Advanced Solid Tumors
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 15. 업데이트됨 · NCT06526819Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT06084481PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05868226Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT05983432Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
피험자 모집 중관찰 연구
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07211178A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 0280, Chicago
- Decatur Memorial Hospital, Decatur
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06926868A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Northwestern University, Chicago
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 23. 업데이트됨 · NCT05005403A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Northwestern Memorial Hospital, Chicago
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT04300556I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Chicago, Chicago
- Loyola University, Maywood
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Chicago Medical Center, Chicago
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 29. 업데이트됨 · NCT04468061A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 11. 4. 업데이트됨 · NCT05902988A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 9. 업데이트됨 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Illinois Cancer Care, Peoria
피험자 모집 중관찰 연구
18세 이상 · 여성 · 2025. 1. 7. 업데이트됨 · NCT06230185ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.